Cargando…

The role of managed care pharmacy in coprescribing naloxone for patients with specific risk: recommendations from the AMCP Addiction Advisory Group

Prescription opioid misuse remains a significant cause of morbidity and mortality associated with drug overdose. Researchers, government agencies, public health interests, and professional organizations support the benefits of naloxone coprescribing for patients on chronic opioid therapy to prevent...

Descripción completa

Detalles Bibliográficos
Autores principales: Skelton, Jann B, Dharbhamalla, Vyishali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372947/
https://www.ncbi.nlm.nih.gov/pubmed/34949114
http://dx.doi.org/10.18553/jmcp.2022.28.1.100
_version_ 1785078459636121600
author Skelton, Jann B
Dharbhamalla, Vyishali
author_facet Skelton, Jann B
Dharbhamalla, Vyishali
author_sort Skelton, Jann B
collection PubMed
description Prescription opioid misuse remains a significant cause of morbidity and mortality associated with drug overdose. Researchers, government agencies, public health interests, and professional organizations support the benefits of naloxone coprescribing for patients on chronic opioid therapy to prevent deaths from opioid overdose. However, gaps remain in the provision of naloxone to patients at risk. Currently, less than 1% of patients who should be prescribed naloxone with their opioid medications obtain a prescription for naloxone, illustrating an opportunity for health care providers to conduct thorough risk assessments for patients taking opioids and coprescribing naloxone to those at risk. There are documented barriers to the provision of naloxone for primary care providers, pharmacists, and patients. Managed care organizations have also created barriers. To better understand and evaluate trends in treatment, coverage, policies, and needs associated with providing health services to patients with substance use disorders, the Academy of Managed Care Pharmacy (AMCP) Addiction Advisory Group conducted a survey in 2019. Eighty percent of the managed behavioral health organizations and 47% of AMCP payer members who responded to the survey encouraged naloxone coprescribing in patients at high risk of overdose; however, no organizations require coprescribing. Health plans, managed care organizations, prescribers, pharmacists, patients, and others have important roles in decreasing the morbidity and mortality associated with opioid overdose. In particular, managed care organizations can take specific and meaningful actions to implement payment policies that improve naloxone coprescribing for patients at risk. In this article, opportunities have been outlined for managed care leadership that actively support public health policies for naloxone coprescribing, and 7 recommendations are presented.
format Online
Article
Text
id pubmed-10372947
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Academy of Managed Care Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-103729472023-07-31 The role of managed care pharmacy in coprescribing naloxone for patients with specific risk: recommendations from the AMCP Addiction Advisory Group Skelton, Jann B Dharbhamalla, Vyishali J Manag Care Spec Pharm Viewpoints Prescription opioid misuse remains a significant cause of morbidity and mortality associated with drug overdose. Researchers, government agencies, public health interests, and professional organizations support the benefits of naloxone coprescribing for patients on chronic opioid therapy to prevent deaths from opioid overdose. However, gaps remain in the provision of naloxone to patients at risk. Currently, less than 1% of patients who should be prescribed naloxone with their opioid medications obtain a prescription for naloxone, illustrating an opportunity for health care providers to conduct thorough risk assessments for patients taking opioids and coprescribing naloxone to those at risk. There are documented barriers to the provision of naloxone for primary care providers, pharmacists, and patients. Managed care organizations have also created barriers. To better understand and evaluate trends in treatment, coverage, policies, and needs associated with providing health services to patients with substance use disorders, the Academy of Managed Care Pharmacy (AMCP) Addiction Advisory Group conducted a survey in 2019. Eighty percent of the managed behavioral health organizations and 47% of AMCP payer members who responded to the survey encouraged naloxone coprescribing in patients at high risk of overdose; however, no organizations require coprescribing. Health plans, managed care organizations, prescribers, pharmacists, patients, and others have important roles in decreasing the morbidity and mortality associated with opioid overdose. In particular, managed care organizations can take specific and meaningful actions to implement payment policies that improve naloxone coprescribing for patients at risk. In this article, opportunities have been outlined for managed care leadership that actively support public health policies for naloxone coprescribing, and 7 recommendations are presented. Academy of Managed Care Pharmacy 2022-01 /pmc/articles/PMC10372947/ /pubmed/34949114 http://dx.doi.org/10.18553/jmcp.2022.28.1.100 Text en Copyright © 2022, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Viewpoints
Skelton, Jann B
Dharbhamalla, Vyishali
The role of managed care pharmacy in coprescribing naloxone for patients with specific risk: recommendations from the AMCP Addiction Advisory Group
title The role of managed care pharmacy in coprescribing naloxone for patients with specific risk: recommendations from the AMCP Addiction Advisory Group
title_full The role of managed care pharmacy in coprescribing naloxone for patients with specific risk: recommendations from the AMCP Addiction Advisory Group
title_fullStr The role of managed care pharmacy in coprescribing naloxone for patients with specific risk: recommendations from the AMCP Addiction Advisory Group
title_full_unstemmed The role of managed care pharmacy in coprescribing naloxone for patients with specific risk: recommendations from the AMCP Addiction Advisory Group
title_short The role of managed care pharmacy in coprescribing naloxone for patients with specific risk: recommendations from the AMCP Addiction Advisory Group
title_sort role of managed care pharmacy in coprescribing naloxone for patients with specific risk: recommendations from the amcp addiction advisory group
topic Viewpoints
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372947/
https://www.ncbi.nlm.nih.gov/pubmed/34949114
http://dx.doi.org/10.18553/jmcp.2022.28.1.100
work_keys_str_mv AT skeltonjannb theroleofmanagedcarepharmacyincoprescribingnaloxoneforpatientswithspecificriskrecommendationsfromtheamcpaddictionadvisorygroup
AT dharbhamallavyishali theroleofmanagedcarepharmacyincoprescribingnaloxoneforpatientswithspecificriskrecommendationsfromtheamcpaddictionadvisorygroup
AT skeltonjannb roleofmanagedcarepharmacyincoprescribingnaloxoneforpatientswithspecificriskrecommendationsfromtheamcpaddictionadvisorygroup
AT dharbhamallavyishali roleofmanagedcarepharmacyincoprescribingnaloxoneforpatientswithspecificriskrecommendationsfromtheamcpaddictionadvisorygroup